Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Eli Lilly rebounded sharply during the quarter as concerns around pricing, penetration, and competition for its GLP-1 weight-loss drugs eased. Stronger-than-expected demand data...
— Andrew Choi & Shivani Vohra
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly and Company
We also continued to add to Eli Lilly and Company in the third quarter. Lilly is best...
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Eli Lilly is a premier multinational pharmaceutical company engaged in the research, development, and commercialization of therapeutics, currently dominating the global market for diabetes and obesity treatments. The manager is...
More institutional theses from Parnassus Growth Equity Fund
GE Vernova is a global industrial leader supplying heavy-duty gas turbines, electrification systems, and electrical grid infrastructure. The manager maintains...
Comfort Systems USA is a premier national mechanical, electrical, and plumbing (MEP) contracting specialist focused on complex commercial and industrial building projects. The manager holds...